The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Larger Will The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Become By 2030 Compared To 2026?
The market for chronic inflammatory demyelinating polyneuropathy (CIDP) has shown robust expansion in recent years. It is forecasted to grow from $2.27 billion in 2025 to $2.46 billion in 2026, at a compound annual growth rate (CAGR) of 8.1%. This historical growth can be attributed to factors such as heightened awareness of rare autoimmune neuropathies, greater accessibility of IVIG therapies, innovations in electrodiagnostic testing, an expansion of specialist neurology care, and more accurate classification of CIDP subtypes.
The market size for chronic inflammatory demyelinating polyneuropathy (cidp) is anticipated to experience significant growth in the coming years. It is projected to expand to $3.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This expansion during the forecast period can be attributed to the increasing development of targeted immunotherapies, a rising emphasis on minimizing treatment side effects, the broadening of remote patient monitoring, a growing demand for therapies that offer sustained remission, and increased investments in rare disease research. Prominent trends expected during the forecast period include the expanding use of IVIG as a first-line therapy, the rising adoption of personalized treatment regimens, the increasing integration of advanced diagnostic tools, the proliferation of home-based treatment models, and an enhanced focus on long-term disease management.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
Which Growth Factors Are Strengthening The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Landscape?
The increasing healthcare expenditure is projected to fuel the expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market in the future. This rise in healthcare spending is fueled by increased investments in medical infrastructure, a growing demand for advanced treatments, expanded insurance coverage, and government efforts to improve healthcare accessibility. Higher healthcare expenditure enables better access to advanced treatments, earlier diagnosis, and more effective management of CIDP, thereby enhancing patient outcomes and quality of life. For instance, in May 2024, the Office for National Statistics, a UK-based government department, stated that total healthcare expenditure witnessed a 5.6% increase in nominal terms from 2022 to 2023, which was a significant acceleration compared to the 0.9% growth observed in 2022. Consequently, the increasing healthcare expenditure is a primary driver for the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
How Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Examined Through Segment Analysis?
The chronic inflammatory demyelinating polyneuropathy (cidp) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administrations
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
What Trends Are Influencing The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook?
Major companies within the chronic inflammatory demyelinating polyneuropathy (CIDP) market are concentrating on innovations like intravenous immunoglobulin (IVIG) therapy to improve the effectiveness of treatments, achieve better patient results, and deliver more precise and efficient immune system modulation for CIDP management. Intravenous immunoglobulin (IVIG) therapy is a medical approach involving the infusion of concentrated antibodies from healthy donors to help regulate the immune system and decrease inflammation in autoimmune conditions. For example, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, announced FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin (IVIG) therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval allows its deployment as an induction therapy, commencing with an initial dose, followed by ongoing maintenance doses to support long-term disease control and enhance neuromuscular function.
Who Are The Businesses Driving Activity In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (cidp) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Hualan Biological Engineering Inc, argenx SE, Bio Products Laboratory Ltd., Kedrion S.p.A, Biotest AG, Hansa Biopharma AB, UCB SA, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Roche Holding AG, Biogen Inc, Momenta Pharmaceuticals, Teijin Pharma Limited, Sanquin Plasma Products BV, Fresenius Kabi AG, Immunovant Sciences GmbH, Akari Therapeutics Plc, GeNeuro Pharmaceuticals, MedDay Pharmaceuticals, HanAll Pharma
Access The Complete Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report:
Which Region Stands As The Largest Contributor To The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2025. The regions covered in the chronic inflammatory demyelinating polyneuropathy (cidp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
Browse Through More Reports Similar to the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2026, By The Business Research Company
Hepatitis B Virus Hbv Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Preventive Vaccines Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report
Viral Hepatitis Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model